AbbVie pins hopes for first major approval in 10 years on hep C drug
- AbbVie is in desperate need of diversification, because it relies on one drug—Humira—for 63% of pits profits.
- AbbVie, which is a spinoff from Abbott Labs, has not had a new approval since 2002 when Humira was approved.
- AbbVie is hoping for an FDA approval for its newly developed hepatitis C (HPV-C) multidrug regimen, which has not been given a brand name yet.
Analysts project that if AbbVie's hep C regimen is approved it could pose a real competitive threat to Gilead's Harvoni. AbbVie's proposed treatment contains several drugs, including paritaprevir and does not require interferon injections.
Though it will most likely require more tablets than Harvoni's once-daily, one-tablet regimen, the high cure rates—92% to 100%—make it an attractive treatment option and a solid bet for the future of AbbVie.